---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-015451"
form_type: "8-K"
ticker: "ABEO"
cik: "0000318306"
company_name: "ABEONA THERAPEUTICS INC."
filed_at: "2026-04-07T23:59:59+00:00"
generated_at: "2026-05-15T07:10:26.620045+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Abeona Therapeutics appoints Keith Goldan as new independent Board member and Audit Committee Chair

## Summary
- Board expanded from 9 to 10 members; Goldan appointed as Class 1 director effective April 1, 2026.
- Goldan named Chair of Audit Committee; Board determined independence under Nasdaq rules.
- Compensation: $50,000 annual cash fee and $150,000 one-time sign-on RSU grant with one-year vesting.
- Goldan currently CFO of Syndax Pharmaceuticals; previously CFO at Optinose and Fibrocell.

## SEC filing metadata
- accession: 0001493152-26-015451
- form_type: 8-K
- ticker: ABEO
- cik: 0000318306
- company_name: ABEONA THERAPEUTICS INC.
- filed_at: 2026-04-07T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/318306/000149315226015451/0001493152-26-015451-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/318306/000149315226015451/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-015451
- JSON: https://secwatch.observer/filing/0001493152-26-015451.json
- Plain text: https://secwatch.observer/filing/0001493152-26-015451.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.